Drugs / HRO761
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05838768 | Jun 2023 → Aug 2027 expected | cancer | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRO761 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05838768 ↗ |
| Known as | WERNER SYNDROME RECQ HELICASE-IN-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068555 ↗ |
| Modality | Small molecule | — CHEMBL6068555 ↗ |
| Route | Oral | “HRO761, is an oral drug” NCT05838768 ↗ |
| Target | WRN | “acts on a protein called Werner (WRN)” NCT05838768 ↗ |